TB-500
These sentences are taken from FDA’s compounding-risk page and, where noted, the July 2026 advisory-committee agenda. They are not a finding that a substance works.
What the opened sources say
Section titled “What the opened sources say”- FDA’s withdrawn-nomination entry is “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500.” The sequence in parentheses is the identifier FDA printed. It is not a synthesis instruction.
- FDA says it has not identified human exposure data for drug products containing that fragment and lacks information to know whether it would cause harm. It also flags immunogenicity and peptide-related impurities for certain routes.
- The 23 July 2026 PCAC agenda lists TB-500 free base and TB-500 acetate for the 503A bulks list, with wound healing as the use FDA says it evaluated. No vote is reported here.
Not stated here
Section titled “Not stated here”Legal effect beyond the words on those pages is not interpreted. No animal or human study is summarized, because none was opened.
This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.
See also
Section titled “See also”Page record
Sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (primary, accessed 2026-11-20)
- July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (primary, accessed 2026-11-20)
Referenced by
- BPC-157
- CJC-1295
- FDA Category 2 and withdrawn nominations
- GHK-Cu
- Ipamorelin
- Melanotan II
- MOTS-c
- PCAC meeting, 23–24 July 2026
- Peptides
A link from another wiki page is not evidence. Facts should point at the sources above.